← All trials
NCT07091630
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 16, 2025
- Primary completion
- Oct 7, 2027
- Completion date
- Jan 23, 2031
- First posted
- Jul 29, 2025
- Last posted
- Oct 7, 2025
- Enrollment
- 160
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- argenxLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.